Decoding the metabolic cipher of dormant cancer cells: molecular mechanisms and therapeutic potentials

Yuao Qin1,2, Junling Zhang1,2, Yuyang Xiao3

  • 1Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, PR China.

Insights

Dormant cancer cells (DCCs) resist treatment and cause recurrence by altering their metabolism. Targeting these metabolic vulnerabilities offers new strategies to improve cancer therapy and prevent relapse.

Area of Science:

  • Oncology
  • Cancer Biology
  • Metabolism

Background:

  • Dormant cancer cells (DCCs) are non-proliferative cells in G0-G1 arrest.
  • DCCs cause therapeutic resistance, immune evasion, and cancer recurrence.
  • Metabolic reprogramming is crucial for DCC survival in nutrient-poor tumor microenvironments (TME).

Purpose of the Study:

  • To review the metabolic characteristics of DCCs.
  • To explore molecular mechanisms of DCC metabolic reprogramming.
  • To discuss therapeutic strategies targeting DCC metabolism for improved treatment outcomes.

Main Methods:

  • Literature review of studies on DCC metabolism.
  • Analysis of molecular mechanisms driving metabolic adaptation in DCCs.
  • Synthesis of information on metabolic pathways and their interactions in DCCs.

Main Results:

  • DCCs exhibit significant metabolic reprogramming for survival and drug resistance.
  • Metabolic heterogeneity among DCC subtypes presents a challenge for eradication.
  • Targeting DCC metabolism shows promise for controlling recurrence.

Conclusions:

  • Understanding DCC metabolic reprogramming is key to overcoming therapeutic resistance.
  • Targeting metabolic vulnerabilities can prevent tumor relapse and improve patient outcomes.
  • Further research into DCC metabolic heterogeneity is needed for effective treatment strategies.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...